Merrill reinstates Millipore at buy

Merrill Lynch analyst Jonathan Groberg reinstated coverage of Millipore Corp. at a buy rating and $80 price objective. According to the analyst, Millipore's growth opportunities, strong management team, recent acquisitions in upstream biotech drug production and attractive valuation create a compelling investment opportunity. Shares of the Billerica, Mass., biopharmaceutical products company were up 77 cents, or 1.16%, at $66.90. (NYSE: MIL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.